<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04817202</url>
  </required_header>
  <id_info>
    <org_study_id>hzVSF_v13-0002</org_study_id>
    <nct_id>NCT04817202</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics of hzVSf-v13 in Healthy Adults (Intravenous and Subcutaneous Administration)</brief_title>
  <official_title>hzVSF-v13 - A Phase I, Double-blind, Placebo-controlled, Single and Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics After Intravenous and Subcutaneous Administration in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImmuneMed, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ImmuneMed, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of the safety, tolerability and pharmacokinetics (PK) characterization of&#xD;
      hzVSF-v13 with single and multiple doses (intravenous and subcutaneous) compared to placebo&#xD;
      in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase I, double-blind, placebo-controlled, single and multiple dose&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 16, 2020</start_date>
  <completion_date type="Anticipated">June 18, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 8, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline QTc interval at each time point</measure>
    <time_frame>Group A1~A7: Day 1 (pre-dose), Day 8, Day 15, Day 22, Day 29, Day 36, Day 50, Day 64, Day 78, Day 92 Group B1~B2: Day 1 (pre-dose), Day 8, Day 15, Day 29, Day 43, Day 57, Day 71, Day 85, Day 98, Day 162</time_frame>
    <description>Safety assessments of hzVSF-v13 by ECG parameter (QTc interval), ECG Bandwidth: 100~300Hz</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic - Cmax</measure>
    <time_frame>Group A1~A7: Predose, 0.25 ~ 2184 hours postdose Group B1~B2: Day 1 (predose ~ 48 hours postdose), Day8, Day15, Day29, Day43, Day 57 (predose, 0.25, 0.5, 1, 2, 4, 6, 8, 10, 12, 24 hours postdose), Day71, Day85, Day98</time_frame>
    <description>Maximum observed Concentration of hzVSF-v13</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic - AUC0-âˆž</measure>
    <time_frame>Group A1~A7: Predose, 0.25 ~ 2184 hours postdose Group B1~B2: Day 1 (predose ~ 48 hours postdose), Day8, Day15, Day29, Day43, Day 57 (predose, 0.25, 0.5, 1, 2, 4, 6, 8, 10, 12, 24 hours postdose), Day71, Day85, Day98</time_frame>
    <description>Area under the plasma concentration-time curve (AUC) from time zero to infinity</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Group A1 (hzVSF-v13 50mg, intravenous, single dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration (intravenous) of 50mg hzVSF-v13 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A2 (hzVSF-v13 100mg, intravenous, single dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration (intravenous) of 100mg hzVSF-v13 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A3 (hzVSF-v13 200mg, intravenous, single dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration (intravenous) of 200mg hzVSF-v13 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A4 (hzVSF-v13 400mg, intravenous, single dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration (intravenous) of 400mg hzVSF-v13 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A5 (hzVSF-v13 800mg, intravenous, single dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration (intravenous) of 800mg hzVSF-v13 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A6 (hzVSF-v13 1200mg, intravenous, single dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration (intravenous) of 1200mg hzVSF-v13 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A7 (hzVSF-v13 100mg, subcutaneous, single dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration (subcutaneous) of 100mg hzVSF-v13 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B1 (hzVSF-v13 100mg, intravenous, multiple dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple administration (intravenous) of 100mg hzVSF-v13 on Day 1, Day 15, Day 29, Day 43, Day 57.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B2 (hzVSF-v13 400mg, intravenous, multiple dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple administration (intravenous) of 400mg hzVSF-v13 on Day 1, Day 15, Day 29, Day 43, Day 57.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (intravenous, single dose)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single administration (intravenous) of placebo on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (subcutaneous, single dose)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single administration (subcutaneous) of placebo on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (intravenous, multiple dose)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple administration (intravenous) of placebo on Day 1, Day 15, Day 29, Day 43, Day 57.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hzVSF-v13 (intravenous, single dose)</intervention_name>
    <description>Dosage form: 50mg / 100mg / 200mg / 400mg / 800mg /1200mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Route: Intravenous Frequency: Dose at Day 1 (single administration)</description>
    <arm_group_label>Group A1 (hzVSF-v13 50mg, intravenous, single dose)</arm_group_label>
    <arm_group_label>Group A2 (hzVSF-v13 100mg, intravenous, single dose)</arm_group_label>
    <arm_group_label>Group A3 (hzVSF-v13 200mg, intravenous, single dose)</arm_group_label>
    <arm_group_label>Group A4 (hzVSF-v13 400mg, intravenous, single dose)</arm_group_label>
    <arm_group_label>Group A5 (hzVSF-v13 800mg, intravenous, single dose)</arm_group_label>
    <arm_group_label>Group A6 (hzVSF-v13 1200mg, intravenous, single dose)</arm_group_label>
    <other_name>a humanized monoclonal antibody (mAb)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hzVSF-v13 (subcutaneous, single dose)</intervention_name>
    <description>Dosage form: 100mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Route: Subcutaneous Frequency: Dose at Day 1 (single administration)</description>
    <arm_group_label>Group A7 (hzVSF-v13 100mg, subcutaneous, single dose)</arm_group_label>
    <other_name>a humanized monoclonal antibody (mAb)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hzVSF-v13 (intravenous, multiple dose)</intervention_name>
    <description>Dosage form: 100mg / 400mg of hzVSF-v13 (40 mg/mL in a 5 mL vial) Route: Intravenous Frequency: Dose at Day 1, Day 15, Day 29, Day 43, Day 57 (multiple administration)</description>
    <arm_group_label>Group B1 (hzVSF-v13 100mg, intravenous, multiple dose)</arm_group_label>
    <arm_group_label>Group B2 (hzVSF-v13 400mg, intravenous, multiple dose)</arm_group_label>
    <other_name>a humanized monoclonal antibody (mAb)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (intravenous, single dose)</intervention_name>
    <description>Dosage form: 0.9% NaCl Solution Route: Intravenous Frequency: Dose at Day 1 (single administration)</description>
    <arm_group_label>Placebo (intravenous, single dose)</arm_group_label>
    <other_name>0.9% Normal saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (subcutaneous, single dose)</intervention_name>
    <description>Dosage form: 0.9% NaCl Solution Route: Subcutaneous Frequency: Dose at Day 1 (single administration)</description>
    <arm_group_label>Placebo (subcutaneous, single dose)</arm_group_label>
    <other_name>0.9% Normal saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (intravenous, multiple dose)</intervention_name>
    <description>Dosage form: 0.9% NaCl Solution Route: Intravenous Frequency: Dose at Day 1, Day 15, Day 29, Day 43, Day 57 (multiple administration)</description>
    <arm_group_label>Placebo (intravenous, multiple dose)</arm_group_label>
    <other_name>0.9% Normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or females (of either childbearing or non-childbearing potential), of any race,&#xD;
             between 18 and 60 years of age, inclusive on day of screening.&#xD;
&#xD;
          -  Body mass index between 18.0 and 32.0 kg/m2, inclusive on day of screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant history or clinical manifestation of any metabolic, allergic,&#xD;
             dermatological, hepatic, renal, hematological, pulmonary, cardiovascular,&#xD;
             gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as&#xD;
             determined by the Investigator (or designee).&#xD;
&#xD;
          -  History of significant hypersensitivity, intolerance, or allergy to any drug compound,&#xD;
             food, or other substance, unless approved by the Investigator (or designee).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>+61-8-70887900 Wabnitz, phD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CMAX Clinical Research Pty Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Byoungok Ahn, phD</last_name>
    <phone>+82-2-527-8391</phone>
    <email>ahnbo@immunemed.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CMAX, Clinical Research Pty Ltd.</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Wabnitz, phD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 22, 2021</study_first_submitted>
  <study_first_submitted_qc>March 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2021</study_first_posted>
  <last_update_submitted>March 24, 2021</last_update_submitted>
  <last_update_submitted_qc>March 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

